PDCD1 and lung carcinoma: Immune checkpoint inhibitors (ICIs), which evoke an antitumor T-cell response by targeting programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) or cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), have advanced the treatment of lung cancer.